Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
IDEXX Laboratories, Inc. logo

NYSE · IDXX

IDEXX Laboratories, Inc.

Healthcare · Medical - Diagnostics & Research

$511.65

Up+$5.17 (+1.02%)

Updated Sep 20, 2026, 11:09 AM

SID Score

4.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
56.52B
P/E ratio
55.18
Dividend yield
0.00%
52-week range
$500.61 – $726.41
Volume
1.12M
Avg. volume
600.64K

Price performance

IDXX price history

1M range · 19 trading sessions · Daily adjusted prices

IDXX closed at $511.65 after 19 trading sessions, down 8.55% for the selected period.

Last close
$511.65
Period change
-8.55%
Period low
$504.70
Period high
$559.51
Daily close
View OHLC price history
IDXX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$506.48$516.43$505.21$511.651.12M
Sep 17, 2026$514.33$514.37$501.98$506.48459.82K
Sep 16, 2026$511.56$520.41$509.02$513.62376.07K
Sep 15, 2026$509.56$516.02$502.40$510.73603.67K
Sep 14, 2026$510.83$515.48$505.015$509.56454.14K
Sep 11, 2026$509.88$511.15$500.61$504.70401.63K
Sep 10, 2026$508.44$514.3001$504.77$506.53422.34K
Sep 9, 2026$517.00$522.49$511.16$515.15556.5K
Sep 8, 2026$528.42$529.015$519.073$520.21613.03K
Sep 4, 2026$522.05$536.085$522.05$535.38407.85K
Sep 3, 2026$542.02$548.85$527.74$529.29590.42K
Sep 2, 2026$546.73$558.42$537.31$538.99655.55K
Sep 1, 2026$555.95$555.95$541.53$545.16458.29K
Aug 31, 2026$547.68$561.24$543.60$556.69698.43K
Aug 28, 2026$547.81$556.01$545.48$554.99340.99K
Aug 27, 2026$549.73$553.11$542.01$545.08340.58K
Aug 26, 2026$544.13$555.705$544.13$553.44349.44K
Aug 25, 2026$555.50$558.0625$549.42$550.01385.74K
Aug 24, 2026$559.21$562.19$554.23$559.51388.93K

Latest IDXX news

The latest Smart Investors Daily articles mentioning IDXX.

Stock researchCompany · Overview

IDXX research

Overview

Company profile and research snapshot.

Company profile

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$803.57
Implied upside
—
Analysts
8
IDXX recent ratings
DateFirmRatingTarget
Aug 11, 2026BarclaysOverweight—
Aug 5, 2026UBSNeutral—
Aug 5, 2026CitigroupNeutral—
Jul 27, 2026UBSNeutral—
Apr 28, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide

IDEXX Laboratories has seen a mixed share price story in recent years, and the question now is whether its current US$506.48 level lines up with the cash flows the business may generate over time. Recent price pressure and fresh AI-driven software ambitions are pulling investor attention back to a simple issue: what are those cash flows worth today? Over the past 5 years the stock has delivered a decline of 25.8%, which puts the focus squarely on whether the cash flow outlook still supports...

Yahoo · Sep 17, 2026

IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus

IDEXX Laboratories (IDXX) drew fresh attention after expanding its Faecal Dx antigen testing platform in the United Kingdom to cover taeniid tapeworms, including Taenia and Echinococcus species, during routine veterinary visits. Recent moves by IDEXX Laboratories, including the Faecal Dx expansion and the CoVetAI acquisition, come as the share price sits at US$506.48. The year-to-date share price return is down 24.4%, but the 3-year total shareholder return remains positive at 15.46%,...

Yahoo · Sep 17, 2026

Is IDEXX’s Expanded Zoonosis Testing Menu Altering The Investment Case For IDEXX Laboratories (IDXX)?

IDEXX Laboratories recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening routine intestinal parasite screening to seven clinically relevant parasite groups and triggering automatic, complimentary Echinococcus RealPCR follow-up tests for positive cases. This expansion deepens the clinical scope and perceived value of Faecal Dx, which has already been used in more than 50 million tests globally since 2012, potentially...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By